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Free-living amebae are present worldwide in soil, dust, and virtually all freshwater
sources. These amebae usually feed on bacteria and do not cause disease. However,
several genera of free-living amebae including Naegleria, Acanthamoeba, Balamuthia,
and Sappina are capable of producing disease in the central nervous system (CNS) of
humans and other animals. Naegleria fowleri produces pnmary amebic
meningoencephalitis (PAM), a rapidly progressing meningoencephalitis which is almost
always fatal. Acanthamoeba species are responsible for a chronic CNS infection known
as granulamatous amebic encephalitis (GAE) and an eye infection called Acanthamoeba
keratitis (John, 1993). Balamuthia mandrillaris causes a chronic CNS infection similar
to that produced by Acanthamoeba, also tenned GAE (John, 1998). Sappina dip/oidea
was recently noted for causing an amebic encephalitis similar to PAM (Gelman et al.,
2001).
Free-living amebae were not considered pathogenic until 1959. In a series of
experiments, Culbertson demonstrated that Acanthamoeba could produce an acute and
fatal meningoencephalitis in laboratory animals when introduced by the intracerebral or
nasal route (Culbertson et al., 1958). In 1965, Fowler and Carter submitted the first
published report of N fowleri causing eNS disease in Australia. In this initial report of 4
patients, the authors suggested the etiologic amebae belonged to the genus
Acanthamoeba. However, subsequent examinations detennined these cases were most
likely caused by N. fowleri. In 1966, Butt reported the first human case of N fowleri
meningoencephalitis in the United States and coined the tenn primary amebic
meningoencephalitis.
1.2 Taxonomy and Biology of N. fowler;
Naegleria is placed in the family Vahlkampfiidae, phylum Saccomastigophora,
subphylm Sarcodina, and order Schizopyrenida. Currently, there are 17 species within
the genus of Naegleria that have been continned based on partial SSUrDNA sequences.
These include N fowleri, N. australiensis, N. lovaniensis, N. gruberi~ N. jadini, N.
andersoni, N clarki, N galeacystis, N. italica, N. jamiesoni, N. morganensis, N.
niuginiensis, N. sturti, N minor, N carteri, N robinsoni, and N pussardi (De Jonckheere
and Brown, 1999). The only species identified as pathogenic in humans and other
animals are N fowleri, N italica, and N australiensis (De Jonckheere, 1994).
Trophozoite, flagellate, and cyst are the 3 stages seen in the lifecycle of
Naegleria. Trophozoites measure 15-30 J.lrn in diameter and are characterized by a large
central nucleolus surrounded by a nuclear membrane without chromatin granules (John,
1998). Trophozoites are elongate and move by broadly rounded, granule-free processes
that erupt from the surface known as lobopodia (Parija and Jayakeerthee, 1999). The
cytoplasm is abundant with vacuoles and mitochondria. Trophozoites feed on bacteria
and rapidly multiply by simple binary fission. Nuclear division is promitotic, meaning
the nucleolus and nuclear membrane persist during nuclear division (John, 1993).
Pathogenic strains of Naegleria have phagocytic structures called 'amoebostomes.'
Amoebostomes are used to engulf particles including bacteria, erythrocytes, yeasts, other
ameba, and cultured mammalian cells (John, 1993). The trophozoites are usually found
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in tissue or cerebrospinal fluid (CSF) and is the only stage of the life cycle that is
responsible for producing PAM.
The flagellate stage occurs as a response to changes in the environment. Factors
inducing enflagellation include nutrient depletion, temperature, phase of growth, and
culture agitation (John, 1998). In this fOIm, N fowleri are biflagellate and have an
elongate cigar or pear-shaped appearance (John, 1993). The flagellates exist as non-
dividing, non-feeding organiSlTIS, which with time will revert to trophozoites.
N. fowleri are also capable of encystment in response to adverse conditions such
as starvation, cold temperatures, drying, and presence of drugs (John, 1998). Encystment
is an adaptive mechanism enabling Naegleria to increase survival. The spherical cysts
have 1 to 2 mucoid plugged pores, or ostioles, and range from 7-15 Jlm in diameter (John,
1998). Excystment is the process by which Naegleria exit their protective coat and
occurs in response to a more favorable environment (John, 1993).
Naegleria spp. are distributed world-wide in soil and virtually all freshwater
sources such as ponds, lakes, and rivers (Parija and Jayakeerthee, 1999). N. fowleri has
also been isolated from poorly chlorinated swimming pools, sewage, hot springs, dust,
thennal discharge of power plants, and heating and ventilation units (Marshall et al.,
1997; Martinez and Visvesvara, 1991). In addition, N. fowleri are thennophilic and can
tolerate temperatures of 40 to 45°C (Marshall et al., 1997).
1.3 Primary Amebic Meningoencephalitis (PAM)
PAM infection nonnally occurs in healthy children or young adults who have
recently been swimming in wann water contaminated with N fowleri (John, 1993). The
amebae gain entry to the nasal cavity during inhalation or aspiration of contaminated
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water. The amebae invade the olfactory lTIUCOSa, penetrate the submucosal nervous
plexus, cross the cribrifonn plate, and gain access into the sub-arachnoid and perivascular
spaces (Parija and Jayakeerthee, 1999). Presumably, the perivascular spaces facilitate the
migration of amebae into the cerebral hemispheres, cerebellum, brain stem, and upper
portions of the spinal cord (John, 1998). Within the brain, the amebae cause extensive
inflammation, necrosis, and hemorrhage.
1.3.1 Clinical Features
The clinical features of PAM develop abruptly within 1 to 5 days after exposure
to N. fowleri. The initial symptoms are characterized by severe frontal headache, fever
(39-40° C), and anexoria, followed by nausea, vomiting, and signs of meningitis (John,
1998). Meningeal irritation may be accompanied by stiff neck, generalized seizures, and
a positive Kemig's sign (Markell et al., 1999). As symptoms persist, the patient may
become confused, irritable, and restless before lapsing into a coma (John, 1993). Death
ensues due to pulmonary edema or cardiorespiratory arrest within 3 to 7 days of the
initial symptoms (Parija and Jayakeerthee, 1999). Other symptoms include convulsions,
photophobia, abnonnalities in taste or smell, increased intracranial pressure, and
cerebellar ataxia (Marshall et al., 1997).
1.3.2 Epidemiology
Although PAM is a rare disease, it has been reported worldwide. Most cases of
PAM have been reported from developed rather than developing countries. This is
probably due to misdiagnosis, inadequate infonnation of PAM, and a very low autopsy
rate in most developing countries. Of the reported cases of PAM, 75% have been from
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Australia, Czechoslovakia, and the USA (John, 1993). In the USA, 67% of the reported
cases have been from the coastal states of Florida, Virginia, and Texas (John, 1998).
PAM occurs more often during the summer months in wann climates due to wanner
waters coupled with increased swimming activity. Thus, it is no surprise that PAM is
more prevalent in nonnal, healthy children or young adults. Fatal cases have been
reported following swimming in lakes, ponds, rivers, thennally polluted streams, coastal
and freshwater, and poorly chlorinated swimming pools. In addition, cases of PAM have
been reported resulting from exposure to cyst-contaminated dust (John, 1993). In a few
instances, the source of exposure could not be detennined (Sugita et a/., 1999).
1.3.4 Treatment of PAM
The mortality rate of patients infected with PAM is greater than 95% (Barnett et
aI., 1996). This grave prognosis is due to the rapid progression of the disease and to the
lack of effective chemotherapeutic agents. Seven patients have been reported to survive
infection with N. fowleri. Two British children were treated with intravenous
amphotericin B (Apley et al., ]970). One Australian patient was given amphotericin B
parenterally and intrathecally (Anderson and Jamieson, 1972). The fourth patient, a
California girl was successfully treated employing amphotericin Band miconazole, both
administered by intravenous and intrathecal routes, along with oral rifampicin (Seidel et
aI., 1982). The fifth case reported was a 61-year-old male from Thailand who recovered
. completely following treatment of intravenous amphotericin B in combination with oral
administration of rifampicin and ketoconazole (Poungvarin and Jariya, 1991). The sixth
survivor was a male from Messina, Italy who was treated with amphotericin B via
intravenous and intrathecal routes (Loschiavo et al., 1993). The last reported survivor
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was from Hong Kong and was treated with amphotericin B, rifampicin, and
chloramphenicol (Wang et a/., 1993).
Presumably, amphotericin B IS the most effective drug against N fowleri.
However, early diagnosis and prompt treatment remaIn a primary requirement for
survival, as evidenced by 2 cases of PAM, which resulted in death in spite of treatment
with amphotericin B (Stevens et al., 1981).
1.4 Experimental Studies of Therapeutic Agents on N. fowleri
Since PAM was identified, a wide range of chemotherapeutic agents has been
tested on N. jow/eri. These agents include antifungals, antiprotozoals, antipsychotics,
antimalarials, and several antibacterial agents. Published data on the effectiveness of
anti-naegleria agents vary depending upon differences among the strains employed, the
media and methods, times of exposure to the drug, and the growth phases of the N.
jowleri cultures when the drug itself is added. The size of inoculum represents a potential
variable that must be considered when detennining phannacological susceptibility of N
fowleri. In addition, definitions of the. minimum inhibitory concentration (MIC) have
varied throughout previous studies. For instance, Scaglia et aI., (1988) defined MIC as
the lowest concentration inhibiting cellular growth without preventing subculturing,
while Duma and Finley, (1976) defined MIC as the lowest concentration of drug at which
growth was 500/0 less than that of the control as detennined visually on the inverted
microscope.
1.4.1 In Vitro Studies of Therapeutic Agents Against N. fowleri
In vitro experiments have provided evidence that antifungal agents are the most
effective drugs against N Jow/eri. Of the antifungals, amphotericin B has the most
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efficacy against N fowleri with MICs ranging from 0.018 - 1· f.lg/ml (Carter, 1969;
Donald et al., 1979; Duma and Finley, 1976; Lee et aI., 1979; Smego and Durack, 1984;
Stevens et al., 1981; and Scaglia et aI., 1988). Of all the agents evaluated against N
fowleri, amphotericin B has been the most studied and is the anti-naeglerial agent to
which all other therapeutic agents are compared.
Scaglia et al., (1988) concluded econazole, an antifungal, to be effective against
N fowleri and N australiensis with an MIC of 4 J.lg/ml. Another antifungal,
ketoconazole, was reported to have an MIC range of 0.31 - 5 flg/ml (Smego and Durack,
1984; Elmsly, 1980) on a New Zealand strain of N. fowleri isolated by Cursons et
al.,(1979). Other studies detennined the activity of the antifungals clotrimazole and
miconazole with MICs ranging from 0.39-1.57 and 0.98-50 flg/ml, respectively, against
several clinical isolates of N. fowleri, including cases from Virginia, Australia, and
Florida, but their effects were less rapid and had less predictability than amphotericin B
(Duma and Finley, 1976; Donald et al., 1979; Elmsly, 1980, and Stevens et al., 1981). In
addition, chlorpromazine and trifluoperazine, which are antipsychotic agents, were shown
to inhibit the growth of the Carter (1966) Australian isolate of N fowleri at
concentrations of 24 and 4.8 Jlg/ml, respectively (Schuster and Mandel, 1984). Lee et al.,
(1979) concluded minocycline, a tetracycline antibiotic, to be effective against the HB-1
strain of Nfowleri with an MIC of2.8 I-lg/ml. This study also detennined minocycline to
be synergistic with amphotericin B in vitro. Other agents found to exhibit synergism
when combined with amphotericin B include rifampin, miconazole, and tetracycline
(Donald et a/., 1979; Seidel et al., 1982; Thong et al., 1979a and 1979b).
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Drugs tested against N jowleri in vitro which were detennined to have minimal or
no activity include: chloroquine, chloramphenicol, clindamycin,. dapsone,
diethylcarbamazine, methotrexate, metronidazole, oxytetracycline, paromomycin,
penicillin G, pentamidine, pnmaqulne, qUInIne, streptomycin, sulfadiazine,
sulfamethoxazole, and trimethoprim (Carter, 1969; Dhu, 1982; Duma and Finley, 1976;
and Thong et al., 1977).
1.4.2 In Vivo Studies in an Experimental Model of PAM
Previous in vivo studies have detennined amphotericin B either alone or in
combination with other drugs is the best treatment for experimental amebic
meningoencephalitis. Ferrante (1982), concluded that 2.5 mglkg amphotericin B
produced 1000/0 survival in mice infected with N fowleri. Furthennore, amphotericin B
at a concentration of 7.5 mglkg produced 60% survival in mice inoculated with either an
Australia isolate or Florida isolate ofN fowleri (Carter, 1969 and Stevens et aI., 1981).
Thong et ale (1979b) reported 2.5 mg/kg amphotericin B in combination with 150
mglkg of rifampin produced 400/0 survival in a mouse model employing the Northcott
strain. However, either 2.5 mglkg amphotericin B or 150 mglkg rifamycin alone was
insufficient to treat an experimental PAM infection (Thong et al., 1979b). In addition,
Thong et al., (1979a) demonstrated a delayed treatment of 72 hours combining 2.5 mg/kg
amphotericin B with 150 mg/kg tetracycline produced 87.50/0 survival in mice inoculated
with the Northcott strain of N. jow/eri. In this same study, 2.5 mglkg amphotericin B
alone produced only 37.5% survival and tetracycline alone at 150 mg/kg produced no
survival.
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Agents tested against N fowleri in vivo and found to be ineffective include:
artemisinin drugs, ketoconazole, metronidazole, miconazole, miconazole in combination
with amphotericin B, miconazole in combination with rifampin, nitrofurazone,
paromomycin, pentamidine, pyrimethamine, pyrimethamine in combination with
sulfadiazine, sulfadiazine, and tetracycline (Carter, 1969; Das et al., 1970; Elmsly et al.,
1980; Ferrante, 1982; Gupta et al., 1995; Stevens et al., 1981; Thong et al., 1978, 1979a,
1979b).
1.5 Significance of Study
The main emphasis of this research was to detennine the in vitro and in vivo
activity of novel chemotherapeutic agents against the Lee (M67) strain of N fowleri in
order to identify drugs that have a greater ability to inhibit the growth ofN fowleri. The
agents chosen for these studies have a mechanism of action or a spectrum of activity that
is similar to drugs already known to be active against Naegleria. Some agents were also
included in this study because of their ability to penetrate the blood-brain barrier. The
agents tested in this study include the antifungals: amphotericin B, liposomal
amphotericin B, and ketoconazole. The protein synthesis inhibitors that were evaluated
in this study were minocycline, azithromycin, quinupristinJdalfopristin, and linezolid.
Other agents tested were rifampin, a RNA synthesis inhibitor, and trifluoperazine, which
is an antipsychotic.
1.5.1 Properties of Antifungal Agents
The major therapeutic application for amphotericin B has been to treat systemic
fungal infections, but it also has activity against some protozoans including Naegleria.
Amphotericin B is reported to combine with membrane sterols, particularly cholesterol
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and ergosterol, thereby increasing the fungal membrane penneability and allowing the
cytoplasmic contents to escape from the cell (Schuster and Rechthand, 1975). Schuster
and Rechthand (1975) have provided in vitro evidence that amphotericin B causes several
ultrastructural changes in N. fowleri. The changes they observed were absence of
pseudopods, abnonnal mitochondria, distortions in nuclear shape, decrease in food
vacuoles, and leakage of the plasma membrane (Schuster and Rechthand, 1975). These
investigators also observed that these ultrastructural abnonnalities were directly
correlated with the time of exposure to amphotericin B. However, amphotericin B
exhibits poor penetration of the CSF, which is the site of PAM infection. In addition,
large amounts of amphotericin B cannot be administered to overcome this difficulty
because it is highly toxic. Amphotericin B is considered the most toxic antibiotic drug in
use today. It has been reported to cause a high rate of nephrotoxicity, acute liver failure,
cardiac arrhythmias, and hematopoietic disorders such as anemia, leukopenia, and
thrombocytopenia (Brenner, 2000).
Although amphotericin B is the most effective anti-naeglerial drug, its narrow
therapeutic index continues to limit its clinical utility. To reduce toxicity, amphotericin B
has been fonnulated in liposomes to allow the administration of higher doses of
amphotericin B with less toxicity to mammalian cells by altering its pharmacokinetics'
and tissue distribution (Clemons and Stevens, 1998). Several preparations of liposomal
amphotericin B have been developed, including Abelcet®, Amphotec®, and
AmBisome®. Each of these preparations has been shown to be useful for the treatment
of cryptococcal meningitis, Leishmania infections, and systemic fungal infections
(Clemons and Stevens, 1998; Yardley and Croft, 1997). Studies have demonstrated that
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higher dosages of liposomal amphotericin B must be administered in order to retain its
therapeutic activity because its potency has been reduced by several fold compared to
free amphotericin B (Clemons and Stevens, 1998). The effects of liposomal
amphotericin B against N fowleri have not been studied and should be evaluated as an
alternative treatment for PAM infection.
Ketoconazole is the other antifungal agent evaluated in this study. Ketoconazole
acts by inhibiting the conversion of lanosterol to ergosterol, which is the principal sterol
in the fungal membrane (Naftalovich, 1991). Ketoconazole has been reported to inhibit
the growth of N. fowleri in vitro (Smego and Durack, 1984). However, Elmsly et al.,
(1980.) reported ketoconazole was not effective in the treatment of experimental amebic
meningoencephalitis. Ketoconazole is less utilized today to treat systemic fungal
infections due to its greater potential for drug interactions by inhibiting the cytochrome
P450 isozyme CYP3A4 (Brenner, 2000).
1.5.2 Properties of Protein Synthesis Inhibitor Agents
Minocycline is a tetracycline antibiotic, which competitively blocks the binding
of tRNA to the 30s subunit of the bacterial ribosome, thereby preventing the addition of
new amino acids to the growing peptide chain (Brenner, 2000). Minocycline is active
against a wide variety of aerobic and anaerobic gram-positive and gram-negative
bacteria. It is also used to treat diseases caused by mycoplasmas, chlamydiae, and
rickettsiae (Brenner, 2000). Minocycline is more lipophilic than other tetracyclines and
will pass into the CSF more readily than the other tetracyclines (Hardman and Limbird,
2001). Minocycline has been detennined to inhibit the growth of N fowleri in vitro,
however the effects of minocycline in vivo have not been evaluated.
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Azithromycin is a macrolide antibiotic that acts on the 50s ribosomal subunit.
This drug blocks pepidyl transferase, the enzyme that catalyzes the formation of peptide
bonds between the nascent peptide and the amino acid attached to the A site (Brenner,
2000). Previous in vitro studies found azithromycin to inhibit the growth of
Acanthamoeba, another opportunistic ameba that causes an encephalitis (Schuster and
Visvesvara, 1998). In addition, Araujo et al. (1988) reported that azithromycin protects
against experimental toxoplasmic encephalitis in a murine model. These studies suggest
azithromycin attains active concentrations in the inflamed eNS and may be promising
against PAM infection.
Quinupristinldalfopristin is a combination of these two semisynthetic pristamycin
derivatives in a 30:70 ratio. Quinupristin and dalfopristin are protein synthesis inhibitors
that act at the 50s subunit. Quinupristin binds to the 50s subunit resulting in the
tennination of protein synthesis. Dalfopristin binds to a site near quinupristin and causes
a confonnational change in the 50s ribosome, synergistically enhancing the binding of
quinupristin at its target site (Hardman and Limbird, 2001). Quinupristin/dalfopristin is
active against aerobic gram-positive organisms such as, vancomycin-resistant strains of
E. faecium and methicillin-susceptiblie strains of S. aureus and S.. pyogenes (Hardman
and Limbird, 2001). In addition, Khan et ale (1999) detennined quinupristinldalfopristin
to have in vitro and in vivo activity against the protozoan Toxoplasma gondii.
Linezolid belongs to the oxazolidinone class of antibacterial agents that act by
inhibiting the process of bacterial protein synthesis by a novel .mechanism. Linezolid
tenninates translation at the initiation step that involves the binding of N-
fonnylmethionyl-tRNA to the 70s ribosome (Zurenko et al., 2001).. Since linezolid
12
inhibits the ribosome-assembly step of protein synthesis, there is no cross resistance with
other antibacterials. Linezolid is active against gram-positive bacteria, including
staphylococci, streptococci, enterococci, gram-positive anaerobic cocci, and gram-
positive rods such as Listeria monocytogenes (Hardman and Limbird, 2001). It has little
activity against most gram-negative aerobic or anaerobic bacteria. The therapeutic uses
of linezolid are reserved for vancomycin-resistant E. faecium; nosocomial pneumonia
caused by methicillin-susceptible and -resistant strains of S. aureus; community-acquired
pneumonia caused by S. pneumonia; and complicated skin and skin-structure infections'
caused by streptococci and S. aureus (Hardman and Limbird, 2001). Regazzi et ale
(2002) reported ·linezolid to have good eNS penetration and could be a promising
candidate for the treatment of CNS infections. Linezolid should be considered in treating
PAM infection due to its unique mechanism of action coupled with the ability to
penetrate the CNS.
1.5.3 Properties of Other Therapeutic Agents
The phenothiazines, a group of drugs to which trifluoperazine belongs, are widely
utilized in medical practice as antipsychotics, but trifluoperazine is also effective against
many strains of staphylococci, Shigella, Vibrio, and Plasmodium· species (Mazumder et
al.,2001). Previous in vitro studies have detennined trifluoperazine to inhibit the growth
of N. fowleri, A. culbertsoni, A. polyphaga, and Balamuthia mandrillaris (Schuster and
Mandel, 1984; Schuster and Visvesvara, 1998). Interestingly, the in vivo effects of
trifluoperazine have not been studied. The mechanism of action by which trifluoperazine
inhibits ameba growth is unknown. Schuster and Mandel, (1984) reported that
trifluoperazine might be interfering with cAMP production in Naegleria sp., but this
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connection has not been demonstrated. Another hypothesis is that trifluoperazine may be
acting at some other point under the influence of calmodulin, or since trifluoperazine is
highly lipophilic it may be affecting the ameba plasma membrane (Schuster and Mandel,
1984). The ability of trifluoperazine to penetrate the blood brain barrier coupled w.ith its
ability to inhibit ameba growth warrants the evaluation of this drug in vivo.
Rifampin, a rifamycin derivative, is a broad spectrum antibiotic that has
significant activity against many bacteria, including mycobacteria (Brenner, 2000). This
drug acts by binding to the p subunit of DNA-dependent RNA polymerase thereby
preventing the enzyme from binding to DNA and consequently inhibiting DNA
transcription (Brenner, 2000). Rifampin has the ability to cross the blood-brain barrier
and reach levels in the CSF that are 10-20 % of the levels in the serum. In addition,
Thong et al., (1979b) reported synergistic activity with a combination of rifampin and
amphotericin B in experimental PAM studies.
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CHAPTER II
RESEARCH DESIGN AND METHODS
2.1 Amebae and Cultivation
The LEE (M67) strain of N fowleri was used in this study. Clifford Nelson
isolated the LEE strain from the cerebrospinal fluid of a 15-year-old female who died
from primary amebic meningoencephalitis in 1968 at the Medical College of Virginia in
Richmond (John, et al., 1993). The LEE (M67) strain is LEE that has been maintained
by 67 passages in mice to retain maximum virulence. The N fowleri LEE (M67) strain
was cultured axenically, without agitation, in Mix medium, which consisted of 0.55%
(w/v) Oxoid liver digest (Unipath LTD., Basingstoke, Hamphshire, England), 0.50%
(w/v) proteose-peptone (Difco Laboratories, Detroit, MI), 0.250/0 (w/v) yeast extract
(Difco Laboratories, Detroit, MI), and 0.30% dextrose (w/v) in Page's ameba saline (0.12
g NaCI, 0.004 g MgS04.7H20, 0.004 g CaCI2.2H20, 0.142 g Na2HP04, 0.136 g
KH22P04 per liter of deionized water) (Page, 1988) supplemented with 4% (v/v) bovine
calf serum (Sigma Chemical Co., St. Louis, MO) and 1 ~g/ml hemin. All components
were autoclaved except bovine serum and hemin, which were sterilized by filtration. The
stock cultures of N. fowleri were maintained at 37° C employing Falcon (Becton




For growth studies, 130 ml of medium was prepared for each trial, inoculated
with 104 amebae/ml from 72 hour stock cultures, and then 30 ml was distributed into 4
separate 50 ml tubes. All therapeutic agents to be studied were solubilized and diluted in
stock solutions from which serial dilutions were made. Using an Eppendorfpipet 0.12 ml
of each drug concentration was added directly to the 30 ml aliquot. Each agent was
tested at 3 different concentrations with each concentration being performed in triplicate.
The control flasks did not receive treatment, unless specified otherwise. The mixture was
vortex-shaken and 10 ml was distributed into 3 separate culture flasks. The culture flasks
were incubated at 37° C and examined daily for growth.
2.3 Cell Counting
To evaluate the effect of each drug on growth, cell counts were perfonned daily
for a period of 96 hours and then at 168 hours. All cell counts were perfonned using a
Coulter Counter (model ZF, Coulter Electronics, Inc., Hialeah, FI) by adding 0.2 ml of
cell suspension to 9.8 ml of electrolyte solution consisting of 0.5% (v/v) fonnalin and
0.40/0 (w/v) NaCI in deionized water. Coulter settings for counting amebae were:
l/amplification 4; 1/aperture current 1; threshold 10; sample volume 0.5 ml. Cuvettes
were vortex-shaken at a setting of 7 for 10 seconds to separate cell aggregates and then
read within 5 minutes. Prior to counting, cuvettes were inverted a few times to resuspend
settled cells and were counted after the bubbles dispersed. Four successive counts were
obtained on each cuvette. The most deviant count for each cuvette was excluded; the
mean of the remaining 9 counts was calculated (3 flasks of 3 counts each). The mean
count for each trial was plotted using Sigma Plot. The minimum inhibitory
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concentration (MIC) for each drug was determined from the graphs and was defined as
the lowest concentration of drug that significantly inhibited amebae growth throughout a
7-day period. The data was analyzed by the student's T-test to detennine whether the
difference between the.control and treated groups were significant
2.4 Therapeutic Agents
The antimicrobial agents obtained from Sigma-Aldrich, Inc. (St. Louis, MO)
include: amphotericin B powder, which consists of 45% amphotericin B, 35%
deoxycholic acid sodium, and 200/0 sodium phosphate; amphotericin B solution, which
consisted of 250 f.lg amphotericin B per ml of water, ketoconazole, minocycline
hydrochloride, trifluoperazine dihydrochloride, and rifampicin crystalline.
AmBisome® (Amphotericin B liposome for injection) was purchased from
Fujisawa Healthcare, Inc. (Deerfield, IL). AmBisome® for injection contains 50 mg of
amphotericin B intercalated into a liposomal membrane, which consists of approximately
213 mg hydrogenated soy phosphatidylcholine; 52 mg cholesterol, NF; 84 mg
distearoylphosphatidyl glycerol; 0.64 mg alpha tocopherol, USP; together with 900 mg
sucrose, NF; and 27 mg disodium succinate hexahydrate as buffer.
Zithromax® (azithromycin for injection) was acquired from Pfizer Inc., (New
York, NY). Zithromax® consists of azithromycin dihydrate and the inactive ingredients:
citric acid and sodium hydroxide.
Synercid® I.V. (quinupristin and dalfopristin powder for injection) was obtained
from Aventis. Synercid® is a sterile lyophilized fonnulation of quinupristin and
dalfopristin in the ratio of 30:70 (w/w).
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Zyvox® powder (linezolid) was a gift from Phannacia phannaceutical company.
Zyvox® consists of linezolid powder.
2.5 In Vitro Drug Dilutions
All drug dilutions were prepared employing sterile techniques and were used
immediately-to minimize loss of activity.
Amphotericin B solution was serially diluted with sterile deionized water to
provide final concentrations of 1 f-!g/ml, 0.1 f-!g/ml, and 0.01 ~g/ml. In ord,er to detennine
a more accurate MIC, amphotericin B solution was further diluted to give final
concentrations of 0.08 ~g/ml, 0.04 f-!g/ml, and 0.02 J.!g/ml.
Liposomal amphotericin B was dissolved and serially diluted in sterile deionized
water to give final concentrations of 1 flg/ml, 0.1 ~g/ml, and 0.01 J.lglml. Based upon the
results for these concentrations, further experiments with liposomal amphotericin B were
perfonned using final concentrations of 0.8 ~g/ml, 0.4 J.lg/ml, and 0.2 ~glml
Minocycline hydrochloride, rifampicin crystalline, and azithromycin were each
dissolved and diluted in sterile deionized water to provide final concentrations of 100
~lg/ml, 10 Ilglml, and 1 J.lg/ml.
Trifluoperazine dihydrochloride, quinupristinldalfopristin, and linezolid were
each dissolved and diluted in sterile deionized water to give final concentrations of 10
f.lglml, 5 ~glml, and 1 Jlg/ml.
Ketoconazole was diluted In methanol to provide final concentrations of 0.5
Jlglml, 0.1 }lglml, and 0.01 Jlg/ml. The controls received an equivalent amount of
methanol in the ketoconazole experiments to detennine whether methanol would affect
amebae growth.
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2.6.!n Vivo Studies: Cell Harvesting
Alnebae were harvested for mouse inoculations after being grown for 72 hours at
37° C in 10m} of mix medium. Amebae were centrifuged at 2,000 X g for 10 minutes in
a Beckman model TJ-6 centrifuge (Beckman Instruments, Inc., Palo Alto, CA). The
amebae were washed in Page saline using the centrifuge and resuspended in the
appropriate amount of Page saline to provide a final concentration of2xl06 amebae/ml.
2.7 Mouse Strain and Inoculations
Male 21-day-old CD-I mice weighing approximately 23 g were used in all
experiments and were purchased from Charles River Laboratories, Inc. (Wilmington,
MA). Prior to experimentation, mice were allowed 3 days to adapt to their new
environment. Mice were housed in plastic cages with 10 mice per cage. All mice were
given free access to water and feed (Purina Lab Chow, Ralston Purina Corp., St. Louis,
MO).
Mice were inoculated by intranasal (i.n.) instillation of a 10 JlI suspension of
amebae in Page saline. While mice were under anesthesia by AErrane®(Isofluorane,
USP, Baxter Caribe Inc., Deerfield, IL) 10 JlI containing 2xl04 ameba was instilled into a
single nare using an Eppendorf pipet.
2.8 Treatment of Experimental Amebic Meningoencephalitis
Treatment began 72 hours after intranasal challenge and persisted for 5 days. For
each set of experiments, the 40 mice were randomly divided into 4 groups with each
group receiving a different treatment. The control group received 0.1 ml intraperitoneal
(i.p.) injections of 0.9% Sodium Chloride Injection (Abbott Labs, Chicago, IL) daily.
The treated groups received 0.1 ml i.p. injections containing the active drug in sufficient
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concentrations to provide the specified dosages (as stated). Injections were made with 8:
1 cc syringe and a 25 gauge 3/8 inch needle into the peritoneal cavity.
2.9 In Vivo Drug Dilutions
Working stock solutions of each drug were prepared using sterile deionized water
for hydration and dilution, except for ketoconazole. The dilutions were stored at either
0° or 4° C in 1 ml aliquots and used within 1 week in order to minimize loss of activity.-
Amphotericin B was dissolved in sterile deionized water to provide final doses of
2.5 mg/kg and 7.5 mg/kg. Liposomal Amphotericin B was dissolved in sterile deionized
water to give final doses of 2.5 mg/kg, 7.5 mglkg, and 25 mg/kg. Minocycline
hydrochloride was dissolved in sterile deionized water to provide final doses of 25 mg/kg
and 50 mg/kg. Azithromycin was dissolved in sterile deionized water to provide final
doses of 25 mg/kg and 75 mglkg. Trifluoperazine dihydrochloride was dissolved with
sterile deionized water to give final doses of 2.5 mg/kg and 7.5 mg/kg.
QuinupristinJdalfopristin was dissolved in sterile deionized water to give a final dose of
150 mg/kg. Ketoconazole was dissolved in 0.1 N HC} and further diluted with sterile
deionized water to provide dosages of 10 mg/kg and 25 mg/kg. The ketoconazole control
group received i.p. injections of 0.01 N HCl. Linezolid was dissolved in sterile deionized
water to provide a final dose of 25 mg/kg and was prepared fresh each day. Linezolid at
75 mglkg was dissolved in sterile deionized water to give the desired concentration in 0.2
ml injections.
Mice were held for 28 days after inoculation and the cumulative percent dead was
recorded on a daily basis. The mean time death (MTD) was calculated for each group of
mice by adding the day of death of each mouse and dividing by the number of mice that
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died within the group. Brain tissue was cultured for amebae from the moribund and dead
mice using 10 ml of mix medium with the addition of penicillin (500 D/mI) and




3.1General Overview of In Vitro Studies
The in vitro studies were perfonned to detennine the activity of a number of anti-
microbial agents against N. fowleri. The Lee (M67) strain of N. fowleri was employed in
all studies. The minimum inhibitory concentration (MIC) was defined as the lowest
concentration that significantly inhibited the growth of N. fowleri throughout a 7-day
period.
3.1.1 Temperature Studies
Pilot studies were perfonned to detennine the growth of the N. fowleri Lee M(67)
strain incubated at different temperatures. The temperatures tested in this study were 23,
30, and 370 C. As shown in Figure 1, the maximal growth of N fowleri was obtained at
37° C. The growth of N. fowleri was slightly reduced at 30° C and considerably reduced
at 23 0 C. Based on these results, the Lee (M67) strain of N. fowleri was incubated at 37°
C in all studies thereafter.
3.1.2 Amphotericin B Studies
The concentrations of amphotericin B used in this study were based upon those
obtained from previous in vitro studies with N fowleri (Carter, 1969; Donald et al., 1979;
Duma and Finley, 1976; Lee et al., 1979; Smego and Durack, 1984; Stevens et aI., 1981;
and Scaglia et al., 1988). Figure 2 depicts the effects of amphotericin B on N. [ow/eri
growth throughout a 7-day course. As shown, 0.1 and 1 J.lg/ml of amphotericin B were
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Figure 1. Growth of N fowleri incubated at different temperatures over a 7-day period.
The data points represent the mean of 2 experiments perfonned in triplicate. The error
bars represent the standard error of the mean for individual data points.
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significantly different from the control and effectively inhibited the growth of N. Jow/eri.
A concentration of 0.01 Jlg/ml amphotericin B had limited activity on the growth of N.
fovvleri. Figure 3 demonstrates the percent inhibition of N fowleri growth over time. As
shown, 0.1 and 1 Jlglml inhibited the growth of N. fowleri greater than 92% from 48
hours and thereafter. The concentration of 0.01 j..lg/ml amphotericin B had a maximal
percent inhibition of 22% at 48 hours and began to deteriorate thereafter. Based upon the
results of this study, different concentrations of amphotericin B were used in order to
detennine a more precise MIC. The results of this study are shown in Figures 4 and 5.
Figure 4 demonstrates N. fowleri growth in the presence of 0.08, 0.04, and 0.02 Jlg/ml of
amphotericin B over time. As shown in Figure 4, the concentration of 0.08 }lg/ml
amphotericin B significantly inhibited the growth of N fowleri and was detennined the
MIC. The concentration of 0.04 J.lg/ml amphotericin B had limited activity on growth,
whereas 0.02 J,lg/ml of amphotericin B did not inhibit the growth of N. jow/eri. Figure 5
represents the percent inhibition of amphotericin B on amebae growth over a 7- day
period. Amphotericin B at 0.02 ~g/ml had a range of inhibition from 500/0 to 15% ,
whereas 0.04 J.lg/ml of amphotericin B inhibited growth from 84% to 41 % throughout the.
7-day period. Amphotericin B at 0.08 f.lg/ml had the most effect on growth with a range
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Figure 2. Effect ofN. fowleri growth to a range of amphotericin B concentrations over a
7-day interval. The data points illustrate the mean of 2 experiments perfonned in
triplicate. The error bars represent the standard error mean of the individual data points.
** significant at p< 0.01
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Figure 4. Effect of N. fowleri growth to a range of amphotericin B concentrations over a
7-day interval.. The data points represent the mean of 2 experiments perfonned in
triplicate. The error bars represent the standard error mean of the individual points.
* significant at p< 0.05 ** significant at p< 0.01
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Figure 5. Percentage inhibition of N fowleri growth in the presence of a range of
amphotericin B concentrations over a 7-day period.
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3.1.3 Liposomal Amphotericin B Studies
The concentrations of liposomal amphotericin B used in this study were the same
as free amphotericinB in order to compare the 2 agents. Figure 6 illustrates the effects of
liposomal amphotericin B on N fowleri throughout a 7-day interval. The concentrations
of 0.01 and 0.1 J.lg/ml liposomal amphotericin B did not effectively inhibit the growth of
N. fowleri, whereas 1J.lg/ml significantly inhibited amebae growth and was detennined to
be the MIC of this study. Figure 7 represents the percentage inhibition of amebae growth
in the presence of liposomal amphotericin B. As shown, a concentration of 1 }.lg/ml
inhibits 98% of amebae growth throughout 168 hours. A concentration of 0.1 J.lglml had
a maximal percentage inhibition of 520/0 at 24 hours, whereas a concentration of 0.01
J.lg/ml of liposomal amphotericin B did not inhibit growth at any time. Based upon the
results of this study, further studies were performed in order to detennine a more accurate
MIC. Figure 8 demonstrates the effect of 0.8, 0.4, and 0.2 J.lglmI of liposomal
amphotericin B on N fowleri growth. As shown in Figure 8, 0.2 and 0.4 J.lg/ml of
liposomal amphotericin B had limited activity on the growth of N fowleri. Liposomal
amphotericin B at 0.8 J.lg/ml significantly inhibited growth of N. fowleri and was
detennined to be the MIC. Percent inhibition of liposomal amphotericin B on N. fowleri
growth is represented in Figure 9. The concentration of 0.8 fJ.g/ml had a percent
inhibition greater than 95% at 48 hours and thereafter. The concentration of 0.4 f.lglml
inhibited 92% of amebae growth at 48 hours and then decreased to 44% by 96 hours.
Liposomal amphotericin B at 0.2 J.lg/ml produced maximal inhibition of 430/0 at 24 hours
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Figure 6. Effects of a range on concentrations of liposomal amphotericin B on N Jowleri
growth over a 7-day period. The data points represent the mean of 2 experiments
perfonned in triplicate. The error bars demonstrate the standard error mean of the
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Figure 8. The effects of a range of concentrations of liposomal amphotericin B on the
growth ofN. fowleri over a 7-day period. The data points represent the mean of 2
experiments perfonned in triplicate. The error bars demonstrate the standard error mean
of the individual points. * significant at p<0.05 ** significant at p < 0.01
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Figure 9. Percent inhibition of N fowleri growth in the presence ofa range of
concentrations of Iiposoma1amphotericin B.
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Studies were conducted to detennine whether there was a difference in the
effectiveness of agitated vs. unagitated liposomal amphotericin B. Figure 10 depicts the
effects of agitated liposomal amphotericin B on the growth of N. fowleri. As shown in
Figure 10, 1 f.lg/ml liposomal amphotericin B significantly inhibited growth ofN fowleri,
whereas 0.1 and 0.01 Jlg/ml were insignificant at inhibiting growth. Therefore, agitation
of the medium did not significantly affect the in vitro activity of liposomal amphotericin
B against N fowleri, except that agitation did increase the doubling rate of the amebae at
the concentrations where growth was not inhibited.
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Figure 10. Effects of agitated liposomal amphotericin B on the growth ofN fowleri.
The data points represent the mean of an experiment perfonned in triplicate.
** significant at p< 0.01
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3.1.4 Ketoconazole Studies
The concentrations used In this study were based upon those obtained from
previous in vitro studies with ketoconazole (Smego and Durack, 1984). The results of
ketoconazole on the growth of N fowleri are illustrated in Figure 11 and ketoconazole
percent inhibition of ameba growth is represented in Figure 12. As shown in Figure 11, a
concentration of 0.01 J.lg/ml was insufficient in repressing ameba growth with a percent
inhibition ranging from 340/0 to 220/0 throughout 168 hours (Figure 12). As shown in
Figure 11, the concentrations of 0.1 and 0.5 Jlg/ml of ketoconazole significantly inhibited
ameba growth. The range of percentage inhibition from 48 to 168 hours was 90-960/0 and
92-970/0, respectively (Figure 12). The MIC was detennined to be 0.1 Jlg/ml of
ketoconazoIe.
3.1.5 Minocycline Studies
The concentrations of minocycline used in this study were derived from prior in
vitro experiments with N. fowleri (Lee et al., 1979). Figure 13 represents the growth of
N. fowleri in the presence of minocycline. The concentrations of 10 and 100 J.lg/ml
significantly repressed the growth of N. Jowleri. Minocycline at 1 J.lg/ml did not inhibit
amebae growth. Figure 14 demonstrates the percentage inhibition of ameba growth in the
presence of minocycline during a 7-day period. Minocycline at a concentration of 1
J.lg/ml produced maximal inhibition of 73~/o at 48 hours, but this effect began to
deteriorate thereafter. The concentrations of 10 and 100 J.!g/ml inhibited ameba growth at
greater than 92% throughout the 7-day course. Maximal percent inhibition of 98% was
obtained at 96 hours at a concentration of 10 Jlg/ml of minocycline and was detennined
the MIC of this study.
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Figure 11. The effects of a range of concentrations of ketoconazole on the growth ofN.
Jow/eri. The data points illustrate the mean of 2 experiments perfonned in triplicate. The
error bars represent the standard error mean of the individual data points.
* significant at p< 0.05 ** significant at p< 0.01
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Figure 13. The effects of a range of concentrations of minocycline on N fowleri growth
over a 7-day interval. The data points demonstrate the mean of2 experiments perfonned
in triplicate. The error bars illustrate the standard error mean of the individual data
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Azithromycin concentrations used in this study were obtained from previous in
vitro studies with the other opportunistic amebae, Acanthamoeba and Balamuthia
(Schuster and Visvesvara, 1998). Figure 15 depicts the effects of azithromycin on N
fowleri growth throughout a 7-day interval. As shown, azithromycin at 10 and 100 J.lg/ml
significantly inhibited the growth ofN [ow/erie A concentration of 1Jlg/ml azithromycin
was not significantly different from the untreated control. The percentage inhibition of
ameba growth in the presence of azithromycin is represented in Figure 16. At the lower
concentration 1 }.lg/ml, inhibition was less than 20% the 7 day study. Percent inhibition
of 10 and 100 fJ.g/mI of azithromycin was greater than 90% on 48 hours and thereafter.
The MIC was detennined to be 10 Jlg/ml of azithromycin.
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Figure 15. The effects of a range on concentrations of azithromycin on the growth ofN.
fowleri over a 7-day period. The data points demonstrate the mean of 2 experiments
perfonned in triplicate. The error bars represent the standard error mean of the individual
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Figure 16. Percent inhibition ofN. fowleri growth in the presence of azithromycin over a
7-day interval.
36
3.1.7 Quinupristin/dalfopristin In Vitro Studies
The concentrations of quinupristinJdalfopristin employed in this study were
obtained from prior in vitro studies with the protozoan Toxoplasma gondii (Khan et al.,
1999). The results of quinupristinldalfopristin are illustrated in Figures 17 and 18.
Figure 17 depicts the effects of quinupristin/dalfopristin on N fowleri growth throughout
7 days. As shown, the concentration of 10 j.!g/mI significantly inhibited the growth of N.
fowleri and was detennined the MIC of this study. The lower concentrations of
quinupristinldalfopristin, 5 and 1 ~g/ml were marginal in their effect on N fowleri
growth. Figure 18 represents the percentage inhibition of quinupristin/dalfopristin on
amebae growth. As shown, at 48 hours 10 Jlg/ml of quinupristinldalfopristin inhibited
58% of growth and continued to inhibit growth throughout day 7.
Quinupristin/dalfopristin at a concentration of 5 ~g/ml inhibited 220/0 of growth at 48
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Figure 17. The effects of a range on concentrations of quinupristin/dalfopristin on the
growth of N fowleri over a 7-day period. The data points illustrate the mean of 2
experiments perfonned in triplicate. The error bars represent the standard error mean of
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Figure 18. Percent inhibition ofN. fowleri growth in the presence of
quinupristin/dalfopristin over a 7-day course.
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3.1.8 Linezolid Stud·es
Linezolid concentrations used in this study were obtained from prior in vitro
experiments employing Mycobacterium marinum (Braback et al., 2002). The effects of
linezolid on N fowleri growth are represented in Figure 19. As shown, linezolid at
concentrations of 1, 5, and 10 J.1g/ml had no effect on N. fowleri growth. Linezolid was
detennined to have an MIC greater than 10 Jlg/ml.
3.1.9 Trifluoperazine Studies
Trifluoperazine concentrations used in this study were detennined by previous in
vitro studies on N. fowleri, Acanthamoeba, and Balamuthia (Schuster and Visvesvara,
1998; Schuster and Mandel, 1984). Figure 20 demonstrates the results of trifluoperazine
on amebae growth. Trifluoperazine at a concentration of 1 Jlg/ml did not effectively
inhibit N. fowleri growth. A concentration of 5 Ilg/ml of trifluoperazine had marginal
effects on ameba growth. Trifluoperazine at a concentration of 10 flg/ml significantly
suppressed the growth of N fowleri and was detetmined the MIC. Figure 21 represents
the percentage inhibition of N. fowleri growth by trifluoperazine. Trifluoperazine at 1
J..lg/ml had a range of iI1hibition from 9-39% with maximal inhibition at 168 hours. At a
concentration of 5 Jlg/ml the range of percent inhibition was 29-480/0 with the highest
inhibition at 168 hours. The range of percent inhibition of 10 J.lg/ml trifluoperazine was
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Figure 19. The effects of a range of concentrations oflinezolid on the growth ofN..







-0- 1 ug/ml Trifluoperazine
-.- 5 ug/ml Trifluoperazine






o 24 48 72 96 120 144 168
Time (hours)
Figure 20. ·The effects of a range of concentrations of trifluoperazine on the growth ofN
fowleri over a 7-day period. The data points represent the mean of 2 experiments
performed in triplicate. The error bars illustrate the standard error mean of the individual
data points. ** significant at p< 0.01
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The concentrations of rifampin used in this study were 1 10, and 100 ~glml and
were based on previous in vitro studies with N. Jowleri (Thong et ai., 1977 and Donald et
al., 1979). Figure 22 illustrates the effects of rifampin on N. fowleri growth. As shown,
rifampin did not significantly inhibit the growth of N fowleri at any of the concentrations
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Figure 22. The effects of a range of concentrations of rifampin on N fowleri growth.
The data points represent the mean of an experiment perfonned in triplicate.
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3.2 Experimental PAl' Studies in a Murine odel
Anti-microbial agents that were effective in vitro were evaluated in an
experimental model of PAM infection. Mice were infected with N. fowleri by intranasal
inoculation. Treatment was begun 72 hours after intranasal challenge and persisted for 5
days. The control groups received 0.1 ml i.p. injections of saline and the treated groups
received 0.1 ml i.p. injections of the active drug, unless stated othetwise. Mice were
observed for 28 days and the cumulative percent dead were recorded on a daily basis. To
confinn the cause of death, brain tissue was cultured for N. fowleri from dead or
moribund mice.
3.2.1 Preliminary In Vivo Results
Preliminary experiments were performed to determine the inoculum size that
produced 100% mortality in the control group. The first inoculum size used was 104
amebae/mouse. Amphotericin B was employed in this experiment using concentrations
of 1.75 and 4 mglkg/day. The results of amphotericin B treatment are presented in Figure
23. As shown, the control group had 200/0 survival and a mean time death of 9.4 days.
Amphotericin B at 1.75 mglkg/day demonstrated 300/0 survival and had a prolonged mean
time to death of 13.8 days as compared to the control group. Mice treated with 4
mg/kg/day of amphotericin B had a 87.50/0 protection rate and a mean time death of 9
days. Based on the results of this experiment, the inoculum size was increased to 2 x 104
amebae per mouse. This inoculum size produced 100% mortality of untreated mice and
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Figure 23. Preliminary results: Treatment of mice inoculated with 1xl 04 N. fow/eri/
mouse with amphotericin B.
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3.2.2 Ampho ericin B In Vivo Studies
The concentrations of amphotericin B used in this study were chosen by previous
in vivo experiments with N fowleri (Carter, 1969; Thong et al., 1979a; Ferrante, 1982).
The effects of amphotericin B on experimental amebic meningoencephalitis are
illustrated in Figure 24. Mice in the untreated gr~up had no survivors and a mean time
death of 9.3 days. Amphotericin B at 2.5 mg/kg/day protected 30% of mice from death
with a mean time death of 7 days. The higher dose of amphotericin B (7.5 mglkg/day)
had a survival rate of 50% and a mean time death of 7.8 days.
3.2.3 Liposomal Amphotericin B In Vivo Studies
Liposomal amphotericin B concentrations were equivalent to free amphotericin B
in order to compare the 2 agents. Figure 25 demonstrates the results of 2.5, 7.5, and 25
mglkg/day of liposomal amphotericin B on experimental PAM. The untreated group had
a mean time death of 8.2 days with no mice surviving infection with N. fowleri.
Liposomal amphotericin B at concentrations of either 2.5, 7.5, or 25 mglkg of body
weight per day protected 300/0 of infected mice from death. The mean time death was 8.3
















---6- 2.5 mg/kg amphotericin B
-.- 7.5mg/kg amphotericin B
o 4 8 12 16 20 24 28
Days
Figure 24. The effects of amphotericin B on experimental amebic meningoencephalitis.















-6- 2.5mglkg liposomal amphotericin B
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Figure 25. The effects of liposomal amphotericin B on experimental amebic
meningoencephalitis. The graph illustrates the percent survival of mice infected with N
fowleri over a 28-day course.
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3.2.4 Ketoconazole In Vivo Studies
The doses of ketoconazole used in this study were obtained from previous in vivo
experiments with N. fowleri (Elmsly et al., 1980). In this experiment, the control group
received i.p. injections of 0.01 N Hel because ketoconazole was solubilized in 0.1 N
Hel. The effects of ketoconazole on experimental amebic meningoencephalitis are
depicted in Figure 26. The control group had no survival with a mean time death of 8
days. I\1ice treated with 10 mg/kg/day of ketoconazole produced 200/0 survival with a
mean time death of 7.6 days. The dose of 25 mglkg/day of ketoconazole produced 300/0
survival in infected mice and a mean time death of7.7 days.
3.2.5 In Vivo Minocycline Studies
Minocycline dosages used in this study were obtained from previous in vivo
experiments on the protozoan Toxoplasma gondii (Romand et al., 1993). The results of
experimental amebic meningoencephalitis treatment with minocycline are illustrated in
Figure 27. Mice treated with 25 mg/kg/day of minocycline took longer to develop
symptoms. Although mortality was still 100%, the mean time death was 8.5 days
compared to 7.8 days in the untreated group. Mice treated with 50 mglkg/day
minocycline had a mere 10% survival and a prolonged mean time death of 9.3 days as






















Figure 26. The effects of ketoconazole on experimental PAM infection. The graph





















o 4 8 12 16 20 24 28
Days
Figure 27. The effects of minocycline on experimental amebic meningoencephalitis.
The graph illustrates the percent survival of mice infected with N fowleri over a 28-day
period.
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3.2.6 Azithromycin In Vivo Studies
Azithromycin doses were chosen based on prior studies on toxoplasmosis in lllice
(Araujo et aL, 1992). Figure 28 represents the effects of treatment with azithromycin on
experimental amebic meningoencephalitis. The untreated group had no survivors with a
mean time death of 7.5 days. Azithromycin administered at dose of 25 mglkglday
protected 40% of infected mice and increased the mean time death to 14.8 days.
Azithromycin at 75 mglkg/day protected 100% of the infected mice against death up to
28 days at which time the experiment was tenninated.
3.2.7 Quinupristin/Dalfopristin In Vivo Studies
The 150 mglkg/day dose of quinupristin/dalfopristin was based on experimental
mice studies with Toxoplasma gondii (Khan et aI., 1999). The effects of
quinupristin/dalfopristin on experimental amebic meningoencephalitis are demonstrated
in Figure 29. Infected mice treated with 150 mglkg/day of quinupristin/dalfopristin
produced 50% survival, whereas mice in the untreated group had no survivors. The mean
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Figure 28. The effects of azithromycin on experimental PAM infection. The graph























Figure 29. The effects of quinupristinldalfopristin on experimental amebic
meningoencephalitis. The graph illustrates the percent survival of mice infected with N
. fowleri throughout a 28-day course.
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3.2.8 Linezolid In Vivo Studies
Linezolid doses were obtained from studies employing experimental bacterial
infections (Ford et a/., 1996). The effects of linezolid on experimental PAM are
demonstrated in Figure 30. Linezolid at 75 mglkg/day was administered in 0.2 ml i.p.
because this concentration was insoluble in the smaller volume. Infected mice receiving
75 mglkg/day linezolid had only 10% survival with a mean time death of 7.7 days. Mice
treated with 25mglkg/day linezolid also produced 100/0 survival, but the mean time death
was prolonged to 8.3 days. The untreated group had no survivors and a mean time death
of8 days.
3.2.9 In Vivo studies with Trifluoperazine
The doses of trifluoperazine employed in this study were based on those used in
previous in vivo experiments with bacteria (Mazumder et al., 2001). The effects of
trifluoperazine on experimental amebic meningoencephalitis are represented in Figure 31.
The untreated group had a mean time death of 7.7 days with no survivors. Mice treated
with 2.5 mg/kg/day of trifluoperazine had a mean time death of 8 days and 20%
protection from death. Mice treated with 7.5 mglkg/day of trifluoperazine were similar to
the 10\\ler dose of trifluoperazine the me.an time death was 7.9 days with a 20% protective
effect from infection. Mice treated with 7.5 mglkg/day trifluoperazine were observably






















Figure 30. The effects of linezolid on experimental PAM infection. The graph






















Figure 31. The effects of trifluoperazine on experimental amebic meningoencephalitis.
The graph represents the percent survival of mice infected with N. fowleri throughout a
28-day period.
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Table II. Summary of In Vivo Results
Drug (mglkg) 0/0 Survival on (day) Mean Time
7 10 14 21 28 Death (day)
Untreated controls 60 5 2 0 0 8.1
Amphotericin B 2.5 40 30 30 30 30 7
7.5 90 50 50 50 50 7.8
Liposomal Amphotericin B 2.5 70 40 30 30 30 8.3
7.5 70 40 30 30 30 8.1
25 80 40 30 30 30 8.3
Ketoconazole 10 70 20 20 20 20 7.6
25 ·70 30 30 30 30 7.7
Minocycline 25 70 10 0 0 0 8.5
50 90 20 10 10 10 9.3
Azithromycin 25 90 90 70 50 40 14.8
75 100 100 100 100 100 >28
Quinupristin/dalfopristin 150 70 50 50 50 50 7.8
Linezolid 25 80 10 10 10 10 8.3
75 60 10 10 10 10 7.7
Trifluoperazine 2.5 70 30 20 20 20 8




4.1 Treatment of PAM Infection
-At ~resent, there exists no satisfactory treatment of the rapidly fatal disease
primary amebic meningoencephalitis (PAM). The antibiotics used to treat bacterial
meningitis are ineffective in N fowleri infections, as are the antiamebic drugs (John,
1993). A variety of drugs have been used to combat infections caused by Naegleria, yet
treatment has been mostly unsuccessful. Of the drugs that have been evaluated against N
fowleri, amphotericin B, an antifungal agent, is the only agent with established clinical
efficacy against PAM infection in humans (Apley, et al., 1970; Anderson and Jamieson,
1972; Seidel et al., 1982; Poungvarin and Jariya, 1991; Loschiavo et al., 1993; Wang et
al., 1993). Several human patients received other drugs in combination with
amphotericin B successfully treated for PAM, even though the therapeutic value of these
drugs has not been demonstrated in N. fowleri infection.
4.2 Experimental Studies of Antifungal Agents on N. fowler;
Of all the agents evaluated against N. fowleri, amphotericin B has been the most
studied and is the anti-naeglerial agent to which all other agents are compared. Based
upon this study and prior data of other investigators, amphotericin B still appears to be
the most potent -and effective agent against N fowleri in vitro. The present study
observed that the MIC of amphotericin B was 0.08 J.lg/ml, which caused a percent
inhibition of greater than 95%. This observation is in general agreement with results
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from previous in vitro studies, which reported MICs of amphotericin B ranging from
0.018 to 1 J.lg/ml (Carter, 1969; Donald et al., 1979; Duma and Finley, 1976; Lee et al.,
1979; Smego and Durack, 1984; Stevens et al., 1981; and Scaglia et aI., 1988). The
reported MICs for amphotericin B vary depending upon differences among the strains of
N. fowleri employed, size of inoculum, and the growth phase of N fowleri cultures when
the drug itself is added.
- Most prior in vivo studies on experimental PAM have evaluated the effectiveness
of amphotericin B against N. Jow/eri. The results of these studies vary widely depending
upon the size of inoculum used, the strain of N fowleri employed, and the time at which
treatment began. Of these previous in vivo experiments, most treatment regimens were
started either before inoculation or 24 hours post-inoculation with N. Jowleri.
The present studies utilized a delayed treatment in which compounds were
administered 72 hours after intranasal inoculation of N fowleri and continued for 5 days.
The 72 hour delayed treatment of experimental amebic meningoencephalitis corresponds
to the· --approximate time an infected patient would present with symptoms and begin
treatment. The results of this in vivo study produced 30% survival of infected mice
receiving 2.5 mg/kg of amphotericin Band 500/0 survival of mice receiving 7.5 mglkg of
amphotericin B daily for 5 days. -However, amphotericin B did not significantly increase
the mean time to death in this study.
Another study reported that amphotericin B at 7.5 mglkg administered 24 hours
pre-inoculation and continuing for 14 days protected 60% of mice from death due to N
fowleri infection (Carter, 1969). Because amphotericin B treatment was begun before
. mice were-infected, the clinical relevance of the study is less significant. Another study
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reported amphotericin B at a dose of 2.5 mg/kg daily for 10 days protected only 10% of
mice infected with the Northcott strain of N. fowler i , when therapy was begun 24 hours
post-inoculation (Thong, et al., 1979b). In contrast, Ferrante (1982) presented evidence
that mice infected with the Northcott strain receiving 2.5 mg/kg of amphot ricin B
beginning 24 hours post-inoculation and continuing for 10 days produced 1000/0 survival.
Thong et al., (1979a) is the only other published report of delayed treatment in an
experimental arnebic meningoencephalitis model. The authors reported that infected
mice receiving 2.5 mglkg of amphotericin B beginning 72 hours post-inoculation and
continuing for 7 days had a survival rate of 37.5%, which is similar to the results of this
study. Overall, the present study produced results with amphotericin B that were similar
to other investigators.
Amphotericin B acts by combining with the sterols ergosterol and cholesterol in
the plasma membrane, and forms pores which causes leakage of the intracellular
contents. Schuster and Rechthand (1975) studied the cytologic effects of amphotericin B
on N. fowleri. The investigators discovered that N fowleri exposed to amphotericin B
would round up and fail to fonn pseudopodia. The ultrastructural abnormalities included
alteration of nuclear shape, increased rough and smooth endoplasmic reticulum, swelling
and degeneration of mitochondria, appearance of autophagic vacuoles, and a decrease in
the number of food vacuoles over that nonnally observed in N fowleri.
Although amphotericin B remains the first choice for treatment of PAM,
amphotericin B therapy is restricted by its acute toxicity and low therapeutic index.
... Amph<?tericin B is probably the most toxic antibiotic in use today. It has been reported to
cause nephrotoxicity in 80% of patients who are treated with it (Brenner, 2000). In
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addition, amphotericin B has been associated with acute liver failure cardiac,
arrhythmias, and hematopoietic disorders such as anemia, leukopenia, and
thrombocytopenia (Brenner, 2000). In an effort to reduce toxicity, amphotericin B has
recently been fonnulated into liposomes, which greatly reduces the drug's oxicity and
extends its half-life (Adler-Moore and Proffitt, 1993). However, it is necessary to
administer larger doses of liposomal amphotericin B in order to obtain the same efficacy
as free amphotericin B in experimental fungal infections.
Because of the high sensitivity of N fowleri to amphotericin B and since this
agent has considerable toxic effects, the present study evaluated the potential substitution
of liposomal amphotericin B for free amphotericin B. The results of this study confinned
liposomal amphotericin B is highly active against N fowleri in vitro, as it inhibited
amebae growth greater than 95% at a concentration of 0.8 J.lg/mL Since free
amphotericin B had 10 times more in vitro activity when compared to liposomal
amphotericin B, it was speculated that amphotericin B was not being released from the
liposomes in vitro. Therefore, experiments were conducted to detennine whether
agitation of the medium would increase the release of amphotericin B from'the liposomes
in vitro. The results of the experiments with agitated liposomal amphotericin -B were
identical to those obtained with unagitated liposon1al amphotericin B experiments. These
results indicate that agitation of the medium does not increase the in vitro activity of
liposomal amphotericin B, and free amphotericin B is more potent than liposomal
amphotericin B 'ort N. fowleri in vitro.
Experiments with mice demonstrated that liposomal amphotericin B is effective in
. the treatment of experimental amebic meningoencephalitis. In this model, the
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administration of either 2.5, 7.5, or 25-mglkg liposomal amphotericin B protected 300/0 of
infected mice. Hence, a dose-response relationship was not observed in this study. The
present study indicates that there are some differences in potency and therap utic efficacy
between free amphotericin Band liposomal amphotericin B. Liposomal amphotericin B
was not as effective as free amphotericin B considering that 7.5 mglkg of free
amphotericin B produced 500/0 survival and the same dose of liposomal amphotericin B
produced only 30% survival of infected mice. The unusual kinetics of liposomal
amphotericin B may partly explain the lack of dose-response found in this study.
However, Alder-Moore and Proffitt (1993) reported that liposomal amphotericin B could
effectively deliver amphotericin B to the brain in sufficient concentrations to either
eliminate or markedly reduce the burden in fungal infections. The phannacokinetics and
activity of liposomal amphotericin B in the treatment of N. fowleri infection remain to be
elucidated.
The other antifungal tested in this study was ketoconazole, which has a
mechani~11). of action similar to amphotericin B. Ketoconazole acts by impairing the
biosynthesis of ergosterol, the main sterol of fungal cell membranes, allowing increased
penneability and leakage of cellular components (Hardman and Limbird, 2001). The
MIC ofketoconazole was 0.1 Ilg/ml with a percent inhibition ofN. fowleri growth greater
than 90%. The only other reported in" vitro study of ketoconazole found a similar effect
on Nfowleri with a MIC of 0.31 J-lg/ml (Smego and Durack, 1984).
In the present study, ketoconazole treatment was associated with increased
survival of infected mice and demonstrated a dose-response relationship. The survival
rate was 20% for mice receiving 10 mglkg ketoconazole and 300/0 survival for those
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treated with 25 mg/kg ketoconazole. The mean ime to death for ketoconazole treated
mice was not different from untreated mice. Elmsly et al., (1980) evaluated the efficacy
of ketoconazole treatment in an experimental PAM model. However, the do age varied
during the experimental treatments up to 20 mglkg i.p..once or twice daily Therapy was
initiated immediately after inoculation with N fowleri. The authors reported
ketoconazole neither reduced mortality nor prolonged survival. .The reason these authors
were unable to show efficacy of ketoconazole could be due to the extremely high
inoculum used in their study, which was 105 amebae/mouse and was almost 10 times
more than that used in the present study. The clinical use of ketoconazole in PAM
infections may be limited due to the poor penetration of ketoconazole into the CSF and
the numerous drug-interactions it causes. Ketoconazole was used in combination with a
low dose of amphotericin Band rifampin in 1 human survivor of PAM (Poungvarin and
Jariya, 1991). However, the mechanism of action of ketoconazole in N fowleri has not
been elucidated.
4.3 Experimental Studies with Protein Synthesis Inhibitors on N. fowler;
Minocycline was included in the present study because of a previously described
in vitro sensitivity of N. fowleri to this drug (Lee et al., 1979). Minocycl·ne is a
tetracycline derivative that inhibits protein synthesis by blocking the binding of tRNA to
the 308 subunit of the bacterial ribosome (Brenner, 2000). The results of this study
. show that minocycline effectively inhibits N fowleri growth at a concentration of 10
~g/ml with a percent inhibition greater than 920/0. Lee et al.,(1979) is the only other
study that has evaluated the in vitro effects of minocycline on N. Jowleri. The authors
. reported minocycline to inhibit the growth of N. fowleri with a MIC of 2.8 J.1g/ml. The'
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differences in MICs are probably due to the dissimilarity between the methods employed
and the definitions of MIC. Lee et al., (1979) defined MIC as the concentration of drug
required to prevent the cytopathic effect of N. fowleri on monkey kidney cell (MKC)
cultures to which an inoculum of approximately 1,000 N fowleri had been added. In
addition;. the inoculum size used in their study was 10 times lower (103 VS. 104
amebae/mouse) than that used in the present study. Nevertheless, both studies
detennined that minocycline effectively inhibited the growth ofN fowleri.
The present in vivo study of minocycline administered at a dose of 25 mg/kg had
little efficacY,as 100% of mice died with a mean time death of 8.5 days. Minocycline at
a dose of 50 mg/kg produced only 100/0 survival in infected mice and the mean time death
was prolonged to 9.3 days. Although minocycline provided limited protection against N
fowleri, mice receiving either dose of minocycline lived longer than the untreated
controls which had a mean time death of 7.8 days.
The present in vivo results are comparable to' another experimental PAM study
conducted with tetracycline, which is in the same class as minocycline. Thong et al.,
(1978) reported tetracycline administered up to 150 mg/kg had minimal activity in the
treatment of experimental PAM. The authors reported 1000/0 mortality of infected mice
and a prolonged mean survival time, which is. comparable to the present study.
Minocycline was expected to be more potent than tetracycline in treating PAM infection
because minocycline is more lipophilic and it reaches higher .concentrations in the eNS
(Hardman and Limbird, 2001). The fact that minocycline has in vitro activity, but was
not effective in vivo is possibly related to the amount of minocycline that is ac~ally
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·reaching the site of infection. However, Derouin et al'
J
(1992) found that minocyclin
was 100% effective in the treatment of encephalitis due to Toxoplasma gondii.
The macrolide antibiotic, azithromycin, was selected for this study on the basis of
a previously described sensitivity of Acanthamoeba to this drug (Schuster and
Visvesvara, 1998). The present study detennined azithromycin to be active against N
/owleri in vitro, as it inhibited growth greater than 90% at a concentration of 1a J.lglml.
Schuster and Visvesvara (1998) concluded azithromycin inhibited Acanthamoeba growth
with a MIC of 0.1 J.lg/ml. Thus, Acanthamoeba species appear to be more .sensitive to
·azithromycin than N./owleri.
The present in vivo studies have indicated superior activity of azithromycin
compared to all other agents evaluated against N. Jowleri. These results revealed that
azithromycin administered at a dose as low as 25 mg/kg protected 400Al of infected mice
from infection. In addition, the mean time death was doubled to 14.8 days compared to
untreated control mice, which had no survivors and a mean time death of 7.5 days.
Treatment with 75 mg/kg of azithromycin resulted in a remarkable survival rate: 10aoAl of
infected mice were still alive with no apparent signs of infection at 28 days when the
experiment was tenninated. Another study found azithromycin to be highly active in a
toxoplasmic encephalitis murine model (Araujo et aI., 1988).
The results of this study and the toxoplasmosis study have suggested that
azithromycin attains active concentrations in the inflamed eNS. The present results also
imply that azithromycin possess a superior efficacy compared to· amphotericin B in
experimental PAM studies. Such results are probably due to the fact of a very long half-
. life of azithromycin and the high accumulation of azithromycin in the tissues that give it
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a greater advantage (Hardman and Limbird, 2001). The mechanism whereby
,azithromycin inhibits or kills N fowleri is not known. It is interesting to postulate that.
either azithromycin alone or in combination with amphotericin B could possibly be an' .
improved treatment of PAM infection in humans. However, further studies hould be
conducted with azithromycin and amphotericin B to detennine the activity of th se drugs
in combination against N. fowleri.
Quinupristinldalfopristin is a novel antimicrobial agent that has a mechanism of
action, similar to azithromycin. Due to the discovery of azithromycin on N. fowleri, it
was considered of interest to investigate the effects of quinupristinJdalfopristin against N.
fowleri. This in vitro study suggested that quinupristinJdalfopristin has moderate activity
against N fowleri, as a concentration of 10 J.lg/ml produced a maximal inhibition of
ameba growth of 60°A>. Due to the in vitro results, the in vivo studies employed a high
dose of quinupristinJdalfopristin, which was ] 50 mglkg daily. The in vivo re ults
revealed that quinupristin/dalfopristin administered at this 'high dose produced 50%
survival of infected mice. The mean time to death was not different from the untreated
control group.
QuinupristinJdalfopristin has been primarily used for the treatment ,of bacteremia,
pneumonia, and skin and soft tissue infections due to drug-resistant gram-positive cocci
(Brenner, 2000). Recently, quinupristin/dalfopristin was determined to exhibit in vitro
and in vivo activity against the protozoan Toxoplasma gondii (Khan et al., 1999). The
investigators reported· quinupristinldalfopristin at 100 and 200 mglkg administered i.p. for
10 days significantly protected 50 and 100% the infected mice against death,
, respectively.
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Linezolid was evaluated in the present study due to its unique mechani m of
action. Linezolid is a novel antibacterial agent that acts by inhibiting the fonnation of the
70S complex by binding to the 50S ribosome near to the interface with the 308 subunit
(Diekema and Jones, 2002). This study was the first to evaluate the effects of linezolid
on N. Jow/eri. In addition, linezolid has been reported to exhibit good penetration of the
CSF and could be a potential treatment of PAM (Regazzi et al.
J
2002).
The present in vitro study evaluated linezolid at concentrations of 1,' 5, and 10
Jlg/ml and found it to have no inhibitory effects on N. fowleri growth. Regardless of the
ineffectiveness oflinezolid in vitro, linezolid was evaluated'in vivo at doses of25 and 75
mglkg. As expected, linezolid offered only 10% protection to infected mice treated with
either dose. In addition, there was no difference in the mean time to d'eath between the
treated and untreated mice. The minimal activity oflinezolid in vitro and in vivo suggests'
a penneability problem in linezolid penetration across the Naegleria cell membrane.
Therefore, linezolid does not seem to be useful in the treatment of PAM.
4.4 Experimental Studies with Other Therapeutic Agents on N. fowler;
Trifluoperazine is a phenothiazine derivative that is commonly used in medical
practice as an antipsychotic. In addition, trifluoperazine has recently been discovered to
have significant antimicrobial activity (Mazumder et al' J 200 I). Trifluoperazine was
evaluated in this study based upon previous in vitro studies with N fow/eri. The in vitro
study indicated 10 ~g/ml of trifluoperazine had an inhibitory effect greater than 90% on
N fowleri growth. The lower concentrations of trifluoperazine (5 and 1 Jlg/ml) were also
moderately effective against N fowleri growth. Schuster and Mandel (1984) first studied
the in vitro activity of trifluoperazine against several strains of N lowleri. The
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investigators reported 4.8 Jlg/ml trifluoperazine inhibited the growth of differen N
fowleri strains 90% or greater. Another in itro study found trifluoperazine inhibited
Acanthamoeba growth by 70 to 90% at 5 and 10 J.!g/ml. These tudie ho that
trifluoperazine has similar activity against N fowleri and Acanthamoeba in vitro.
The present experiments with mice portrayed trifluoperazine to have limited
efficacy in the treatment of experimental amebic meningoencephalitis. In this model
administration of either 2.5 or 7.5 mglkg of trifluoperazine protected only 20% of
infected mice. Thus, a dose-response relationship was not observed in this study. In
addition, the mean time of death was not significantly different among the treated and
untreated mice. This study was the first attempt to treat experimental amebic
meningoencephalitis infection with trifluoperazine.
Due to the high in vitro sensitivity of N fowleri to trifluoperazine, the in vivo
results were somewhat disappointing. Since trifluoperazine is highly lipophilic, the low
in vivo activity probably correlates with the antimicrobial· action of trifluoperazine within
the brain. The mode of action of trifluoperazine has not been fully established in
Naegleria. Schuster and Twomey, (1983) studied the in vitro effects of trifluoperazine
on nonpathogenic Naegleria gruberi. The investigators found trifluoperazine to have an
inhibitory effect on flagellation and on the trophic growth of N. gruberi. Schuster and
Mandel, (1984) postulated several different in vitro modes of action for trifluoperazine on
N. fowleri growth. First, trifluoperazine may be interfering with cAMP production in
Naegleria sp., although this association has not been established. Second, trifluoperazine
could be inhibiting the calcium regulatory protein, calmodulin at some point in
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Naegleria. The other theory of tritluoperazine action on Naegleria is SIn e
trifluoperazine is higWy lipophilic, it may affecting the ameba pIa rna membrane.
Rifampin did not have in vitro activity at any of the concentrations evaluated
against N fowleri in the present study. The MIC of rifampin was determined to the
greater than 100 ~g/ml. These results are similar to a previous in vitro study by Donald
et al., (1979). The authors tested rifampin at a range of concentrations between 10 and
500 J.lg/ml against the MsT strain ofN fowleri and found no inhibition of growth at any
of the concentrations tested. Their study detennined rifampin to have a MIC of greater
than 500 J.lg/ml.· In contrast, Thong et a/., (1977) found rifampin at a concentration of
100 J.lg/ml to significantly inhibit N. fowleri growth.
Due to the in vitro results of this study and the results of Donald et al., (1979),
rifampin was not included in the in vivo studies. 'Rifampin was previously studied in an
experimental murine model of PAM by Thong et al., (1979b). The investigators
administered rifampin at 50, 100, and 150-mg/kg 24 hours post-inoculation daily for 10
days to infected mice. Their study detennined rifampin had minimal activity with a
1000/0 mortality rate of treated mice. However, the authors demonstrated synergistic
activity between rifampin and amphotericin B in an experimental model of PAM. In
addition, rifampin has been successfully utilized in 3 human cases of PAM in triple
combination with amphotericin Band 1 of the following compounds: ketoconazole,
miconazole, or chloramphenicol.
4.5 Summary and Future Directions
In conclusion, the -antifungal agents appear to have the most in vitro activity
against N. fowleri, as the MICs of the antifungals were all less than 1 Jlg/mI. In addition,
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rninocycline, azithromycin, quinupristin/dalfopristin, and trifluoperazine also
demonstrated in vitro activity against N fowleri with MICs of 10 Jlglml. Rifampin and
linezolid did not exhibit in vitro activity against N fowleri at the concentrations tested
and the MICs were detennined to be greater than 100 and 10 J.lglml, respectively.
However, the sensitivity of N. fowleri to a therapeutic agent in vitro does not
directly correlate with the drug's in vivo activity. These results have indicated superior I
activity for azithromycin treatment of experimental PAM infection. Amphotericin B
treatment had the next best in vivo activity. Lipid preparations of amphotericin Bare
inferior to conventional amphotericin B, and the lipid preparations did not exhibit a dose-
,response relationship in this study. Ketoconazole was effective in the treatment of
experimental PAM and clearly demonstrated a dose-response relationship. A high dose
of quinupristinldalfopristin offered protection to mice infected with N. Jow/eri.
Trifluoperazine demonstrated limited in vivo efficacy, and also did not exhibit a dose-
response relationship. Finally, minocycline and linezolid offered minimal protection in
this experimental PAM model.
It is proposed that the experimental PAM model using a delayed treatment will
provide a more reliable basis for therapeutic agents that will be effective in patients
s'uffering from PAM infection. Azithromycin has great promise in the clinical treatment
of patients suffering from PAM infection. Further studies should be conducted in an
experimental model of PAM to evaluate whether a combination of azithromycin and
amphotericin B are synergistic. In addition, the therapeutic agents: ketoconazole,
quinupristin/dalfopristin, and trifluoperazine, which displayed marginal activity, should·
. be evaluated for synergy with amphotericin B. It is possible that amphotericin B, by
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increasing the penneability of the ameba membrane, could allow the other therapeutic
agents to more effectively penetrate the ameba.
Even though minocycline and linezolid did -not offer protection to infected mice,
these agents should also be considered in synergy studies with amphotericin B.
According to Thong et al., (1979a and 1979b), rifampin and tetracycline did not protect. ,
infected mice when administered alone, but the effects of these drugs. were. potientated
when combined with amphotericin B.
Finally, the study with liposomal amphotericin B had ma~~inal efficacy in mice
infected with N. fowleri, with no dose-response relationship. It would also be of interest
to evaluate liposomal amphotericin B combined with other therapeuti~ agents for
potientation or synergistic effects.
Future studies to detennine the mechanism of action of ~zithromycin and other
active drugs on N. fowleri would also be helpful in identifying other potential therapeutic
agents for treating PAM infection.
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